Novo Nordisk A/S Equity-NMS: NVO

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$158.09

52W high :

$158.11

1Y :

40.08%

5Y :

223.69%

Shares O/S :

1.74 B

Market cap :

277.29 B

What is the share price of Novo Nordisk A/S today?

Novo Nordisk A/S (NVO) share price as of April 2, 2023, is $159.13. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Novo Nordisk A/S?

Yes, Indian Investors can invest in the Novo Nordisk A/S (NVO) Share by opening an international trading account with Angel One.

How can I purchase Novo Nordisk A/S shares in India?

Purchasing Novo Nordisk A/S (NVO) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Novo Nordisk A/S (NVO) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Novo Nordisk A/S?

Yes, you can purchase fractional shares of Novo Nordisk A/S (NVO) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Novo Nordisk A/S?

The market capitalization of Novo Nordisk A/S on April 2, 2023, is $277.29 B.

In which sector Novo Nordisk A/S belongs?

Novo Nordisk A/S operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Novo Nordisk A/S stocks?

In order to invest in Novo Nordisk A/S (NVO) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.